All mice were bred and maintained in our rodent facility and monitored for blood glucose prior to infection to ensure that only pre-diabetic mice were analyzed.
Mice were fed ad libitum a high-cholesterol diet and made diabetic with intraperitoneal injections of streptozotocin for 7 days; and monitored for blood glucose and HbA1c once weekly until euthanized.
In this group, 34 patients were monitored continuously for glucose parameters for 7 days by using CGMS.
Blood glucose was monitored for up to 2 weeks, and only the rats with blood glucose >16.6 mM were used for further study.
Mice were monitored for diabetes by measuring blood glucose every 4 days for a maximum period of 21 days with a Glucomatic® ESPRIT Apparatus (Bayer, France).
After either 60 or 120 days of insulin treatment, the islet transplant or insulin implant were removed and blood glucose levels monitored for 30 days.
Following PIT or sham transplantation, blood glucose was monitored for 3 weeks.
After treatment, animals were monitored for body weight and blood glucose.
We monitored blood glucose for 24 h postoperatively.
Although we have used an intravenous continuous glucose monitor for blood glucose management to avoid hypoglycemia, there has been a problem with interruption of blood glucose measurement caused by blood removal failure [1].
